Characteristics | Platinum-sensitive recurrence (n = 49) N (%) | Platinum-resistant recurrence (n = 22) N (%) | P value |
---|---|---|---|
Age | 0.395 | ||
≤ 60 years | 40 (71.4) | 16 (28.6) | |
> 60 years | 9 (60.0) | 6 (40.0) | |
Residual disease | 0.783 | ||
≤ 1 cm | 25 (67.6) | 12 (32.4) | |
> 1 cm | 24 (70.6) | 10 (29.4) | |
FIGO stage | 0.115 | ||
Stage III | 46 (71.9) | 18 (28.1) | |
Stage IV | 3 (42.9) | 4 (57.1) | |
Histologic types | 0.946 | ||
High-grade serous carcinoma | 44 (69.8) | 19 (30.2) | |
Low-grade serous carcinoma | 2 (66.7) | 1 (33.3) | |
Mucinous | 1 (50.0) | 1 (50.0) | |
Endometrioid | 2 (66.7) | 1 (33.3) | |
Normalization of CA125 level after 3 cycles of chemotherapy | < 0.001 | ||
Yes | 43 (82.7) | 9 (17.3) | |
No | 6 (31.6) | 13 (68.4) |